Aptiv Solutions Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Southborough MA United States (1980)
Status: Acquired by ICON (2014)

Organization Overview

First Clinical Trial
2004
NCT00596752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fulcrum Pharma | Fulcrum Pharma (Europe) Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 4)

Campylobacter Infections (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Hepatolenticular Degeneration (Phase 1)

Infections (Phase 2)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Ovarian Neoplasms (Phase 3)

Peripheral Arterial Disease (Phase 4)

Renal Insufficiency (Phase 4)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 26